State of the art: optimal medical therapy - competing with or complementary to revascularisation in patients with coronary artery disease?

The role of coronary revascularisation with PCI and CABG in patients with stable and unstable coronary artery disease (CAD) is well established and there is a general consensus among guidelines as regards the indications for coronary revascularisation. Although revascularisation has undoubtedly revolutionised the treatment of CAD, it is vital to understand the recent advances and importance of the concomitant use of evidence-based optimal medical therapy (OMT). In contemporary practice, OMT should include an antiplatelet agent (or dual antiplatelet therapy when indicated) and a lipid-lowering drug for all patients, and a beta-blocker and an ACE inhibitor (or angiotensin receptor blocker) for the vast majority of patients, along with addressing cardiac risk factors and lifestyle management. OMT is the recommended initial choice for patients with stable angina pectoris, and the indication for revascularisation would be persistence of symptoms despite OMT and/or improvement of prognosis. For patients with acute coronary syndromes or those who underwent coronary revascularisation with either PCI or CABG, long-term use of OMT improves clinical outcomes and prognosis.